Cargando…

LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study

PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions...

Descripción completa

Detalles Bibliográficos
Autores principales: de Blank, Peter M K, Lange, Katharine R, Xing, Mengqi, Salehabadi, Sedigheh Mirzaei, Srivatava, Deokumar, Brinkman, Tara M, Ness, Kirsten K, Oeffinger, Kevin C, Neglia, Joseph, Krull, Kevin R, Yasui, Yutaka, Nathan, Paul, Howell, Rebecca, Turcotte, Lucie, Leisenring, Wendy, Armstrong, Gregory T, Bowers, Daniel C, Okcu, M Fatih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164667/
http://dx.doi.org/10.1093/neuonc/noac079.330
_version_ 1784720189200269312
author de Blank, Peter M K
Lange, Katharine R
Xing, Mengqi
Salehabadi, Sedigheh Mirzaei
Srivatava, Deokumar
Brinkman, Tara M
Ness, Kirsten K
Oeffinger, Kevin C
Neglia, Joseph
Krull, Kevin R
Yasui, Yutaka
Nathan, Paul
Howell, Rebecca
Turcotte, Lucie
Leisenring, Wendy
Armstrong, Gregory T
Bowers, Daniel C
Okcu, M Fatih
author_facet de Blank, Peter M K
Lange, Katharine R
Xing, Mengqi
Salehabadi, Sedigheh Mirzaei
Srivatava, Deokumar
Brinkman, Tara M
Ness, Kirsten K
Oeffinger, Kevin C
Neglia, Joseph
Krull, Kevin R
Yasui, Yutaka
Nathan, Paul
Howell, Rebecca
Turcotte, Lucie
Leisenring, Wendy
Armstrong, Gregory T
Bowers, Daniel C
Okcu, M Fatih
author_sort de Blank, Peter M K
collection PubMed
description PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions (CHCs, CTCAE grading criteria) were evaluated in the Childhood Cancer Survivor Study among 5-year survivors of glioma diagnosed 1970-1999. Outcomes were evaluated by diagnosis decade and by treatment exposures received ≤5 years following diagnosis (surgery-only, chemotherapy ± surgery, and cranial radiation ± surgery or chemotherapy). Relative risk (RRs) with 95%CIs estimated long-term outcomes using multivariable piecewise exponential models. RESULTS: Among 2,684 eligible survivors (age at diagnosis (median [range]), 7 years [0-20 years]; time from diagnosis, 24 years [5-48 years]), exposure to cranial radiation decreased [51% (1970s), 45% (1980s), 25% (1990s)] along with late tumor recurrence (>5 & ≤15 years from diagnosis) [9.8% (1970s), 8.8% (1980s), 5.0% (1990s)]. The 15-year cumulative incidence of late mortality was 10.3% (1970s), 6.5% (1980s), and 6.0% (1990s) (p<0.001, comparison of cumulative incidence curves). The 15-year cumulative incidence of grade 3-5 CHCs was 19.7% (1970s), 17.8% (1980s), and 14.2% (1990s) (p<0.0001). A reduction in SN incidence was not observed. In multivariable analyses excluding treatment exposure, later diagnosis (1990s vs. 1970s) was associated with lower risk of late mortality, grade 3-5 CHCs and SNs. Inclusion of treatment exposure in the model attenuated the effect of diagnosis decade. Radiation or chemotherapy exposure increased risk compared to surgery alone for late mortality (radiation RR 4.95, 95%CI 3.79-6.47; chemotherapy RR 2.88, 95%CI 1.85-4.48), CHCs (radiation RR 4.02, 95%CI 3.28-4.94; chemotherapy RR 1.66, 95%CI 1.13-2.45), and SNs (radiation RR 4.02, 95%CI 3.06-6.13, chemotherapy RR 2.08, 95%CI 1.03-4.23)). CONCLUSION: Late mortality and CHCs decreased in childhood glioma survivors diagnosed from 1970-1999 largely due to therapy changes, particularly avoidance of cranial radiation, without increased late recurrence.
format Online
Article
Text
id pubmed-9164667
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91646672022-06-05 LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study de Blank, Peter M K Lange, Katharine R Xing, Mengqi Salehabadi, Sedigheh Mirzaei Srivatava, Deokumar Brinkman, Tara M Ness, Kirsten K Oeffinger, Kevin C Neglia, Joseph Krull, Kevin R Yasui, Yutaka Nathan, Paul Howell, Rebecca Turcotte, Lucie Leisenring, Wendy Armstrong, Gregory T Bowers, Daniel C Okcu, M Fatih Neuro Oncol Low Grade Glioma PURPOSE: Pediatric low-grade glioma therapy has evolved to delay or eliminate radiation. The impact of therapy changes on long-term outcomes remains unknown. METHODS: Cumulative incidence of late mortality (death >5 years from diagnosis), subsequent neoplasms (SNs), and chronic health conditions (CHCs, CTCAE grading criteria) were evaluated in the Childhood Cancer Survivor Study among 5-year survivors of glioma diagnosed 1970-1999. Outcomes were evaluated by diagnosis decade and by treatment exposures received ≤5 years following diagnosis (surgery-only, chemotherapy ± surgery, and cranial radiation ± surgery or chemotherapy). Relative risk (RRs) with 95%CIs estimated long-term outcomes using multivariable piecewise exponential models. RESULTS: Among 2,684 eligible survivors (age at diagnosis (median [range]), 7 years [0-20 years]; time from diagnosis, 24 years [5-48 years]), exposure to cranial radiation decreased [51% (1970s), 45% (1980s), 25% (1990s)] along with late tumor recurrence (>5 & ≤15 years from diagnosis) [9.8% (1970s), 8.8% (1980s), 5.0% (1990s)]. The 15-year cumulative incidence of late mortality was 10.3% (1970s), 6.5% (1980s), and 6.0% (1990s) (p<0.001, comparison of cumulative incidence curves). The 15-year cumulative incidence of grade 3-5 CHCs was 19.7% (1970s), 17.8% (1980s), and 14.2% (1990s) (p<0.0001). A reduction in SN incidence was not observed. In multivariable analyses excluding treatment exposure, later diagnosis (1990s vs. 1970s) was associated with lower risk of late mortality, grade 3-5 CHCs and SNs. Inclusion of treatment exposure in the model attenuated the effect of diagnosis decade. Radiation or chemotherapy exposure increased risk compared to surgery alone for late mortality (radiation RR 4.95, 95%CI 3.79-6.47; chemotherapy RR 2.88, 95%CI 1.85-4.48), CHCs (radiation RR 4.02, 95%CI 3.28-4.94; chemotherapy RR 1.66, 95%CI 1.13-2.45), and SNs (radiation RR 4.02, 95%CI 3.06-6.13, chemotherapy RR 2.08, 95%CI 1.03-4.23)). CONCLUSION: Late mortality and CHCs decreased in childhood glioma survivors diagnosed from 1970-1999 largely due to therapy changes, particularly avoidance of cranial radiation, without increased late recurrence. Oxford University Press 2022-06-03 /pmc/articles/PMC9164667/ http://dx.doi.org/10.1093/neuonc/noac079.330 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Low Grade Glioma
de Blank, Peter M K
Lange, Katharine R
Xing, Mengqi
Salehabadi, Sedigheh Mirzaei
Srivatava, Deokumar
Brinkman, Tara M
Ness, Kirsten K
Oeffinger, Kevin C
Neglia, Joseph
Krull, Kevin R
Yasui, Yutaka
Nathan, Paul
Howell, Rebecca
Turcotte, Lucie
Leisenring, Wendy
Armstrong, Gregory T
Bowers, Daniel C
Okcu, M Fatih
LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title_full LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title_fullStr LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title_full_unstemmed LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title_short LGG-15. Late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the Childhood Cancer Survivor Study
title_sort lgg-15. late mortality and morbidity of adult survivors of childhood glioma treated across three decades: a report from the childhood cancer survivor study
topic Low Grade Glioma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164667/
http://dx.doi.org/10.1093/neuonc/noac079.330
work_keys_str_mv AT deblankpetermk lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT langekathariner lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT xingmengqi lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT salehabadisedighehmirzaei lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT srivatavadeokumar lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT brinkmantaram lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT nesskirstenk lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT oeffingerkevinc lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT negliajoseph lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT krullkevinr lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT yasuiyutaka lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT nathanpaul lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT howellrebecca lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT turcottelucie lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT leisenringwendy lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT armstronggregoryt lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT bowersdanielc lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy
AT okcumfatih lgg15latemortalityandmorbidityofadultsurvivorsofchildhoodgliomatreatedacrossthreedecadesareportfromthechildhoodcancersurvivorstudy